Cargando…
Case report: Bullous pemphigoid arising in a patient with scleroderma and multiple sclerosis
BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune-blistering disease, clinically characterized by erythematous urticarial plaques, blisters, and intense pruritus, induced by autoantibodies against two proteins of the dermo-epidermal junction, BP180 and BP230. A large number of autoim...
Autores principales: | Moro, Francesco, Mariotti, Feliciana, Pira, Anna, De Luca, Naomi, Didona, Biagio, Pagnanelli, Gianluca, Di Zenzo, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773387/ https://www.ncbi.nlm.nih.gov/pubmed/36569153 http://dx.doi.org/10.3389/fmed.2022.1055045 |
Ejemplares similares
-
Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine
por: Pira, Anna, et al.
Publicado: (2023) -
Case report: bullous pemphigoid development underlies dystrophic epidermolysis bullosa disease worsening
por: Di Zenzo, Giovanni, et al.
Publicado: (2022) -
156 COVID-19 vaccine is a risk factor accelerating time to bullous pemphigoid onset
por: Pira, A., et al.
Publicado: (2023) -
The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets
por: Maglie, Roberto, et al.
Publicado: (2023) -
Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study
por: Maronese, Carlo Alberto, et al.
Publicado: (2022)